Professional Marketing briefs: October 2012

Professional Marketing briefs: October 2012
Professional Marketing briefs: October 2012

Content Marketing Institute and MedCityNews.com are holding their first Content Marketing World Summit in November. The ­November 7–8 meeting will be held in Cleveland, OH, and will focus on healthcare marketing. Topics will include social media and content creation for hospitals, content marketing metrics and ROI and managing the content marketing process.

Sanofi was expected to clarify layoff plans at meetings September 25 and October 3, reported Reuters, which attributed the information to union sources. Unions said they expect Sanofi to cut about 2,500 research and support jobs in France. Sanofi told ­Reuters meeting dates had not been set, but that is presenting its employment plans to the works council in September.

Although the FDA is on a roll of obesity-drug approvals, word is that branded slimming drugs may have competition, reported the Associated Press. The wire service quoted analyst Thomas Wei as saying he believes doctors will prescribe Qsymia's components instead of the branded drug. Qsymia consists of topiratmate and phentermine, both of which are available as generics.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.